Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
WALTHAM, Mass., Nov. 09, 2016 -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2016.
| Tuesday, November 15th, 8:30 a.m. Eastern Time | ||
| Dial in (domestic): | 877-324-1976 | |
| Dial in (international): | 631-291-4550 | |
| Conference ID: | 13333032 | |
A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Investor Contact: Steve DiPalma Interleukin Genetics, Inc. (508) 654-4572 [email protected] Media Contact: Jennifer Moritz Zer0 to 5ive for Interleukin Genetics (917) 748-4006 [email protected]
